CNTX Stock Overview
A biopharmaceutical company, develops products for the treatment of solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Context Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.50 |
| 52 Week High | US$2.75 |
| 52 Week Low | US$0.79 |
| Beta | 2.25 |
| 11 Month Change | -34.78% |
| 3 Month Change | -38.78% |
| 1 Year Change | 75.52% |
| 33 Year Change | -79.05% |
| 5 Year Change | n/a |
| Change since IPO | -70.59% |
Recent News & Updates
Recent updates
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Aug 15
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02Shareholder Returns
| CNTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.0% | 3.4% | 1.6% |
| 1Y | 75.5% | 14.2% | 32.3% |
Return vs Industry: CNTX exceeded the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: CNTX exceeded the US Market which returned 32.4% over the past year.
Price Volatility
| CNTX volatility | |
|---|---|
| CNTX Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CNTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 5 | Martin Lehr | www.contexttherapeutics.com |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. Fundamentals Summary
| CNTX fundamental statistics | |
|---|---|
| Market cap | US$110.25m |
| Earnings (TTM) | -US$30.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs CNTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.15m |
| Earnings | -US$30.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CNTX perform over the long term?
See historical performance and comparison